Human cancers harboring oncogenic mutant K-Ras are susceptible to changes in cellular ROS because of their metabolic reprogramming, and ROS-elevating agents are effective in their growth inhibition (Arambula et al, 2016; McCall et al, 2017; Foo & Pervaiz, 2019). Here, KRAS is linked to cancer.